OmniAb, Inc.
omniab.comWhat Do They Do?
Licenses antibody-discovery technology and provides research services to pharmaceutical and biotechnology companies and academic institutions, helping them find antibody candidates for drug development.
10-K for FY2025, filed Mar 4, 2026OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to…View ↗
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods…View ↗
We partner with pharmaceutical and biotechnology companies and leading academic institutions that vary in size, geography and therapeutic…View ↗
How Do They Make Money?
Partners pay for technology access upfront or annually, for research services as work is performed, and may owe milestone payments when development or regulatory milestones are reached; royalties track partner product sales. xPloration brings in sales of instruments and consumables.
10-K for FY2025, filed Mar 4, 2026Our license agreements with pharmaceutical and biotechnology partners generally include: (i) upfront or, in some instances, annual payments…View ↗
The Company recognizes service revenue for contracted R&D services performed for partners over time. The Company measures its progress…View ↗
The Company includes contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate…View ↗
For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the…View ↗
For xPloration instruments and related consumables sold by the Company, control transfers to the customer at a point in time. To indicate…View ↗
-
10-K for FY2025, filed Mar 4, 2026
FY2025 revenue by product or service ↗
$18.7M
-
10-K for FY2025, filed Mar 4, 2026
$18.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License and milestone revenue
|
52%
FY2022: 66%
|
License and milestone revenue, FY2025
$9.8M Sources
|
|
|
Service revenue
Recurring
10-K for FY2025, filed Mar 4, 2026 |
39%
FY2022: 32%
|
Service revenue, FY2025
$7.3M Sources
|
Recurring |
|
xPloration revenue
Sold outright
|
4.0% |
xPloration revenue, FY2025
$754K Sources
|
Sold outright |
|
Royalty revenue
Licensed
|
4.7%
FY2022: 2.3%
|
Royalty revenue, FY2025
$878K Sources
|
Licensed |
Who Are Their Customers?
Pharmaceutical and biotechnology companies and academic institutions partner for antibody discovery; some use OmniAb technologies directly in their own laboratories.
10-K for FY2025, filed Mar 4, 2026
Do Revenues Turn Into Profits?
No. It lost $64.8M in FY2025.
10-K for FY2025, filed Mar 4, 2026
−$69MView ↗
10-K for FY2025, filed Mar 4, 2026
−$64.8MView ↗
10-K for FY2025, filed Mar 4, 2026
−$37MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Oct 30, 2026
−$15.7MView ↗
- ▼ −5% (Loss)
- vs −$16.5M in Q3 FY2025
10-Q for Q3 FY2026, filed Oct 30, 2026
Open tableView ↗
-
Aug 6, 2026
OmniAb raised its 2026 revenue and cash outlook
Revenue outlook rose to $32 million to $36 million; year-end cash outlook rose to $37 million to $41 million.
Sources
8-K, filed Aug 6, 2026
OmniAb revises 2026 financial guidance and now expects revenue to be in the range of $32 million to $36 million, versus $28 million to $33…View ↗
Shrinking. Revenue fell 46% in 4 years, from $34.7M in FY2021 to $18.7M in FY2025, about 14% a year.
Broader discovery formats
The older report focuses on antibody discovery and antibody formats. The latest also describes peptide discovery and smaller antibody-derived binding domains as offerings of its platform.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 4, 2026Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies…View ↗
Who Do They Compete With?
Competes with AbCellera Biologics, Ablexis, Alloy Therapeutics, Biocytogen Pharmaceuticals (Beijing), Nona Biosciences, Leveragen, Regeneron Pharmaceuticals, Twist Bioscience, Bruker, DPBIO, Sartorius, Fluidic Sciences, Charles River Labs, Evotec, Metrion Biosciences, and WuXi AppTec
10-K for FY2025, filed Mar 4, 2026in discovery using genetically-engineered rodents, we face technical competition from companies that provide access to similar…View ↗
Loading...
